Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

PRP showdown: which injection eases hip pain best?

NCT ID NCT05497349

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two versions of platelet-rich plasma (PRP) injections—one with white blood cells and one without—to see which better reduces pain and stiffness in people with hip osteoarthritis. About 230 adults with mild to moderate hip OA will receive ultrasound-guided injections and be followed for a year. The goal is to find the most effective way to ease symptoms and improve daily function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 230 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signs and symptoms of hip OA (pain intensity of at least 4 points and not more than 8 of VAS pain - 0-10 scale in the previous week); * Radiographic signs of hip OA (Grade 1-2 according to Tonnis classification) or MRI signs (chondropathy or minimal labrum degeneration without acute lesions) even if Grade 0. * Unilateral involvement; Hemoglobin \> 11 g/dl; * Platelet count \> 150,000 plt/mm3 (Recently performed CBC examination); * Negative serological tests for HBsAg, HCV Ab, HIV-1-2 Ab * No clinically significant electrocardiographic changes (Recently performed ECG). * Ability and consent of patients to actively participate in clinical follow-up;- Signature of informed consent. Exclusion Criteria: * Patients unable to express consent; * Patients undergoing infiltration of other substance in the previous 6 months; * Patients undergoing lower limb surgery to be treated in the previous 12 months; * Patients with malignant neoplasms; * Patients with rheumatic diseases;- Patients with uncontrolled diabetes;-Patients with hematological diseases (coagulopathies); * Patients on anticoagulant-antiaggregant therapy that cannot be discontinued for at least 3 days prior to blood collection; * Patients with uncontrolled thyroid metabolic disorders; * Patients abusing alcoholic beverages, drugs or medications; * Body Mass Index \> 30; * Patients who have taken NSAIDs in the 3 days prior to blood draw; * Patients with cardiovascular disease for whom 300 ml blood draw would be contraindicated; * Patients with recently performed CBC examination with Hb\< 11 g/dl and Platelet values \< 150,000 plt/mm3. * Positive serological tests for HBsAg, HCV Ab, HIV-1-2 Ab * Pregnant and/or fertile women. * Pain intensity less than 4 points or greater than 8 in accordance with the VAS scale. * Patients with other hip pathologies: acetabular protrusion, concentric migration of the femoral head, presence of excessive deformity resulting from acetabular or femoral head dysplasia, collapse deformity, and deformed femoral head sequelae of Perthes disease or osteonecrosis of the femoral head. * Previous extensive surgery of the reference joint (osteotomy around the hip, open or arthroscopic osteochondroplasty for femoro-acetabular conflict).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Ortopedico Rizzoli

    RECRUITING

    Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.